Comparative Pharmacology
Head-to-head clinical analysis: DRALSERP versus SERPASIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DRALSERP versus SERPASIL.
DRALSERP vs SERPASIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Depletes monoamines (serotonin, norepinephrine, dopamine) from central and peripheral nerve terminals by binding to and inhibiting the vesicular monoamine transporter 2 (VMAT2), impairing storage and leading to enzymatic degradation.
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
0.25 mg orally once daily; may increase by 0.25 mg every 2 weeks to a maximum of 1 mg daily in divided doses.
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
None Documented
None Documented
Terminal elimination half-life is 45 to 50 hours; clinically significant as drug accumulates with repeated dosing, requiring careful titration.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
Primarily hepatic metabolism to inactive metabolites; less than 1% excreted unchanged in urine; approximately 10% eliminated in feces.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Category C
Category C
Antihypertensive
Antihypertensive